Afinitor (Everolimus)

everolimus 5 mg tablet, 30 · ORAL · PBS code 10131F

AUTHORITY_REQUIRED

What it costs

AU$796.7 PBS-determined price per 30 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

• First listed on the PBS: 2014-09-01.
• Repeats: 5.
• PBS program: GE.

Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Metastatic or unresectable, well-differentiated malignant pancreatic neuroendocrine tumour (pNET)

Continuing treatment

Patient must have previously been issued with an authority prescription for this drug; AND

Patient must not have disease progression; AND

The treatment must be as monotherapy.

Patients who have progressive disease with this drug are no longer eligible for PBS-subsidised treatment with this drug.

Sponsor: Novartis Pharmaceuticals Australia Pty Limited ABN 18 004 244 160

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.